A broader genomic risk picture to guide AML treatment
Official title: Towards a more generalizable genomic risk classification for acute myeloid leukemia (AML)
Funded at Ohio State University · NIH-11389404 · Data updated 2026-11-12
AIM to refine how genetic information guides treatment decisions for adults with acute myeloid leukemia by looking at how inherited and recurrent mutations affect risk.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | September 18, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $648,220 |
| NIH project number | 5R01CA284595-04 |
| Project ID | NIH-11389404 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with acute myeloid leukemia who will undergo genomic testing as part of their clinical care.
✕Less likely to help
Patients without access to comprehensive genomic testing or whose treatment decisions are not influenced by genetic risk may see limited benefit.
What this research studies
This project focuses on adults with AML and analyzes both inherited and tumor-related genetic features to improve how risk is classified in everyday care. Researchers plan to extend previous genome studies to better understand how genetic backgrounds modify the prognostic value of AML mutations and to identify new molecular features that may influence disease development or therapy response. The work will use large-scale genomic data and statistical methods to strengthen confidence in which genes matter for prognosis, potentially tailoring treatment choices to the individual patient. The study is grounded in real-world clinical practice and aims to translate complex genetics into clearer guidance for clinicians and patients.
Why it matters
Potential benefit: If successful, patients could receive more accurate risk stratification and personalized treatment plans based on their unique genetic profile.
How similar studies have gone: Previous studies showed that incorporating genetic context improves prognostic models, and this work aims to strengthen and broaden that approach.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Eisfeld, Ann-Kathrin — Ohio State University
- Study coordinator: Eisfeld, Ann-Kathrin
Related research
Other NIH-funded projects on the same topics.
-
Acute Myeloid Leukemia: Improving Targeted Therapies through Genetically Defined PDX Models
Researchers are using patient-like leukemia models to develop therapies that target specific genetic features of AML to improve survival.
-
RNA Polymerase II as a Therapeutic Target in AML with RAS Activation
This project explores a new way to treat a common type of blood cancer (AML) by blocking a key machinery (RNA Polymerase II) that cancer cells use when the RAS signaling pathway is overactive.
-
SHP2 and BCL2 inhibitors together for AML growth and resistance
A patient-focused look at whether combining SHP2 inhibitors with a BCL2 inhibitor can slow or stop AML, especially in people whose disease has FLT3 or KIT mutations.
-
Targeting RNA polymerase II in AML with RAS pathway activation
This project tests drugs that block RNA polymerase II to help people whose acute myeloid leukemia has RAS pathway activation and is resistant to FLT3 inhibitors.
-
New treatment approach for myelodysplastic syndrome and acute myeloid leukemia
This project aims to develop a new antibody-based therapy to help people with MDS or AML, especially older or frail patients who cannot tolerate high-dose chemotherapy.
-
Making genetic risk predictions more accurate for adults with acute myeloid leukemia
This project is developing better genetic-based risk categories to help guide treatment decisions for adults with acute myeloid leukemia.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.